LSD1 Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2024

The Lysine-specific histone demethylase 1A (LSD1), also known as lysine (K)-specific demethylase 1A (KDM1A), is a protein that in humans is encoded by the KDM1A gene. LSD1 inhibitors are a class of drugs that target this enzyme and modulate its activity. The mechanism of action of LSD1 inhibitors involves binding to the enzyme's active site and blocking its function, which leads to alterations in gene expression and epigenetic modifications, which can have various effects on cellular processes and disease states. The mechanism of action of LSD1 Inhibitors is the removal of methyl groups from lysine residues on histone proteins, leading to changes in chromatin structure and gene expression. By binding to the active site, LSD1 inhibitors prevent the enzyme from accessing its substrate and carrying out demethylation reactions. This inhibition results in the accumulation of methylated lysine residues on histones. The accumulation of methylated lysine residues caused by LSD1 inhibition affects the structure of chromatin and the accessibility of DNA to transcription factors and other regulatory proteins. This can lead to changes in gene expression patterns. LSD1 Inhibitors are used to treat acute myelogenous leukemia, leukemia, lymphoma, and acute lymphocytic leukemia, to name a few.

Moreover, the increasing prevalence of leukemia and lymphoma conditions are the key drivers for the LSD1 Inhibitors market. For instance, according to the World Cancer Research Fund 2020, There were an estimated 18.1 million cancer cases around the world and 4,74,519 new cases of leukemia in 2020. The global cancer burden is expected to increase by 28.4 million cases by 2040, a 47% rise from 2020. For instance, Oryzon's Vafidemstat (ORY-2001)  for treating Multiple sclerosis is in the various stages of clinical studies.

Key Market Developments:

• In July 2023, Oryzon completed phase 2, a randomized, open-label study to evaluate the efficacy and tolerability of treatment with Vafidemstat in combination with standard-of-care treatment to prevent Acute Respiratory Distress Syndrome (ARDS) in adult severely ill patients with COVID-19.

Drugs under the Pipeline for LSD1 Inhibitors:

   Bomedemstat (MK-3543)

   Vafidemstat (ORY-2001)

   Iadademstat (ORY-1001)

   Domatinostat (4SC-202)

   Pulrodemstat (CC-90011)

   Seclidemstat (SP2577)

   INCB59872

   GSK2879552

   TAK-418

   GS-5801

   JBI-802

   SYHA1807

   TAS1440

Clinical Activity and Developments of LSD1 Inhibitors:

• Till July 2023, more than 10 companies have approximately 13 molecules targetting the many cancers. For these molecules, more than 32 clinical trials are being conducted and the majority are in phase-2, and phase-3 clinical trials by the players across the globe. For instance
• In February 2019, Imago BioSciences has completed phase 1/2, a multi-center, open label study to assess the safety, steady-state pharmacokinetics and pharmacodynamics of IMG-7289 (Bomedemstat) with and without ATRA (Tretinoin) in patients with advanced myeloid malignancies.